act

Bacteria Tag Team Tumors with T Cells

A team at Columbia University School of Engineering and Applied Science has developed a technique to enhance chimeric antigen receptor (CAR) T cell therapy in solid tumors. The technique involves engineering E. coli bacteria, that naturally tend to accumulate in the immune privileged core of solid tumors. The bacteria have been engineered to interact with […]




act

Best Practices for Successfully Transitioning a Patient Services Hub

Today’s guest post comes from Josh Marsh, Vice President and General Manager, Sonexus™ Access and Patient Support at Cardinal Health

Josh discusses challenges manufacturers may face when outsourcing patient support programs. He outlines a process that smoothly transitions hubs and minimizes disruptions for patients and healthcare providers.

To learn more, download the 3-step guide to patient hub transitions.

Read on for Josh’s insights.
Read more »
       




act

Hospitals Are Relying More on PBMs to Manage Manufacturers' 340B Contract Pharmacy Restrictions: DCI's 2024 Market Analysis (rerun)

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors.

Click here to see the original post from June 2024.



The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market reveals that:
  • About 33,000 pharmacy locations—more than half of the entire U.S. pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program. 
  • Five multi-billion-dollar, for-profit, publicly traded pharmacy chains and pharmacy benefit managers (PBMs)—Cigna (via Express Scripts), CVS Health, UnitedHealth Group (via OptumRx), and Walgreens, Walmart—continue to dominate the 340B contract pharmacy market.
  • Federal grantees are aligned primarily with the vertically intergated organizations' retail pharmacies, while hospitals rely on mail and specialty pharmacies.
Over the past four years, manufacturers’ restrictions on 340B contract pharmacies have led hospitals to deepen their relationships with the largest PBMs—even as those PBMs have simultaneously limited hospitals’ direct participation in specialty pharmacy networks.

For an updated look at what’s next for the 340B contract pharmacy market, join Adam J. Fein, Ph.D., on June 21 for his latest live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook.
Read more »
       




act

Informa Connect’s PBM Contracting Summit

Informa Connect’s PBM Contracting Summit
December 10-11, 2024 | Chicago, IL
Drug Channels readers save 10% with code 24DRCH10*

Experts from across the US come together each year at the PBM Contracting Summit to gain innovative and practical contracting strategies, master PBM innovation and design, improve patient care management and rising costs, understand the current legislative issues impacting contract negotiations and more. Join us in Chicago (or virtually) where you’ll benefit from two days of learning, education and networking, and will return to the office having mastered the complex PBM landscape.

You’ll hear from Matthew Gibbs, Pharm.D., Pharmacy Transformation Leader of Blue Shield of California as he leads a comprehensive discussion on the PBM landscape over the last year, and delves into the evolving trends and emerging challenges shaping the current industry today.

Other expert and thought leaders from within the industry are slated to present deep dive sessions, workshops and panels that will answer your most pressing questions:
  • What are the latest legislative updates and proposed federal bills impacting PBM operations?
  • What's on the horizon for alternative PBMs? What are the top intricacies of rebate eligibility? What are the market impacts of innovative models such as Mark Cuban's Cost Plus Drugs and Amazon's pharmacy model?
  • What can be learned from the J&J lawsuit? Review the expansion of data access and the importance of employer's fiduciary duties.
  • What are the challenges of vertical integration?
  • How do PBMs manage their contracting processes with plan sponsors to create successful contracts?
  • What are the most effective strategies for spread pricing and reimbursement models?
  • What is the best solution to navigate the challenges of the 340B drug pricing program and PBM contracting?
  • What is the best way to design and optimize benefits for covering GLP-1s?
  • How can I ensure compliance with ERISA requirements?
  • What are the latest developments in copay maximizer and accumulator programs?
  • What market dynamics and barriers are impacting pricing and demand?
  • What can be learned from the economic landscape of biosimilars and specialty therapeutics?
  • And much more!

View the agenda for the PBM Contracting Summit to see the complete picture – the program, speakers, and more, visit www.informaconnect.com/pbm-contracting for further details and to register. Drug Channels readers will save 10% off when they use code 24DRCH10 and register prior to November 8, 2024.*

*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates or other offers. Other restrictions may apply.


The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).
       




act

The 340B Program Reached $66 Billion in 2023—Up 23% vs. 2022: Analyzing the Numbers and HRSA’s Curious Actions

Reality has again failed to support the spin surrounding the 340B Drug Pricing Program.

For 2023, discounted purchases under the 340B program reached a record $66.3 billion—an astounding $12.6 billion (+23.4%) higher than its 2022 counterpart. The gross-to-net difference between list prices and discounted 340B purchases also grew, to $57.8 billion (+$5.5 billion). 340B purchases are now almost 40% larger than Medicaid’s prescription drug purchases.

Hospitals again accounted for 87% of 340B purchases for 2023. Purchases at every 340B covered entity type grew, despite drug prices that grew more slowly than overall inflation.

Lobbyists claim that manufacturers’ 340B contract pharmacy changes are “stripping billions of dollars from the healthcare safety net.” But every year, the data tell a very different story. Only in the U.S. healthcare system can billions more in payments and spreads be considered a cut.

Read on for full details and our analysis, along with fresh details of troubling behavior by the Health Resources and Services Administration (HRSA).
Read more »
       




act

How the Perfect Storm Will Impact Patient Support Programming in 2025 and Beyond

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx.

Chris examines three key trends that will affect patient support programs: the Inflation Reduction Act (IRA), legal/regulatory battles over copay adjustment programs, and uncertainties following a national election. He then outlines three actions that should guide manufacturers' preparation.

To learn more, register for ConnectiveRx’s free webinar on December 11: The Perfect Storm? Patient Support Programming in 2025 and Beyond.

Read on for Chris’s insights.
Read more »
       




act

Bonus Episode: Fast Facts on the ACRO D&I Grants Program

ACRO’s Good Clinical Podcast is back with bonus episode! Host Sophia McLeod sat down with Tafoya Hubbard and Kristen Surdam to discuss ACRO’s new D&I Site Resource Grants Program.

The post Bonus Episode: Fast Facts on the ACRO D&I Grants Program first appeared on ACRO.




act

Sequestration Has Less Impact on FDA? Just Not True

“The Hill” newspaper recently reported that: “a survey of federal budgets devoted to developing and enforcing regulations found that many agencies will spend more in 2013 and 2014 than in previous years, indicating that the writing and enforcing of new regulations is largely unimpeded by the massive cuts, known as sequestration.” That certainly sounds authoritative…until you look at the analysis. In fact, the report’s authors appear to know nothing about the federal budget and have used inherently unreliable data in calculating FY 13 and FY 14 spending levels. One can only hope that the authors—allegedly academic experts--know more about regulatory policy than they do about federal budgets.




act

Rhode Island Governor Vetoes Consumer Data Privacy Act

On June 25th, Rhode Island Governor Daniel McKee transmitted without signature (effectively a pocket veto) the Rhode Island Data Transparency and Privacy Protection Act (SB 2500 / HB 7787). The act is based on the Washington Privacy Act model but diverges from the prevalent forms of that model in two ways. First, the act contains a unique […]




act

ASBM/GaBI 2024 webinar on BIOSIMILAR RED TAPE ELIMINATION ACT (S2305)

<p> <b>BIOSIMILAR RED TAPE ELIMINATION ACT (S2305):</b><br /> <b><i>Weakening FDA Regulatory Standards for Biosimilars, Undermining Physician Confidence and Jeopardizing Patient Health</i></b><br /><b>31 October 2024&nbsp;|&nbsp;</b><b><a href="https://youtu.be/X6-dYZ7fjhM" target="_blank">WATCH REPLAY</a></b></p>




act

The Biotech Startup Contraction Continues… And That’s A Good Thing

Venture creation in biotech is witnessing a sustained contraction. After the pandemic bubble’s over-indulgence, the venture ecosystem appears to have reset its pace of launching new startups. According to the latest Pitchbook data, venture creation in biotech hit its slowest

The post The Biotech Startup Contraction Continues… And That’s A Good Thing appeared first on LifeSciVC.




act

Waiver of Informed Consent - proposed changes in the 21st Century Cures Act

Adam Feuerstein points out - and expresses considerable alarm over - an overlooked clause in the 21st Century Cures Act:


In another tweet, he suggests that the act will "decimate" informed consent in drug trials. Subsequent responses and retweets  did nothing to clarify the situation, and if anything tended to spread, rather than address, Feuerstein's confusion.

Below is a quick recap of the current regulatory context and a real-life example of where the new wording may be helpful. In short, though, I think it's safe to say:


  1. Waiving informed consent is not new; it's already permitted under current regs
  2. The standards for obtaining a waiver of consent are stringent
  3. They may, in fact, be too stringent in a small number of situations
  4. The act may, in fact, be helpful in those situations
  5. Feuerstein may, in fact, need to chill out a little bit


(For the purposes of this discussion, I’m talking about drug trials, but I believe the device trial situation is parallel.)

Section 505(i) - the section this act proposes to amend - instructs the Secretary of Health and Human Services to propagate rules regarding clinical research. Subsection 4 addresses informed consent:

…the manufacturer, or the sponsor of the investigation, require[e] that experts using such drugs for investigational purposes certify to such manufacturer or sponsor that they will inform any human beings to whom such drugs, or any controls used in connection therewith, are being administered, or their representatives, that such drugs are being used for investigational purposes and will obtain the consent of such human beings or their representatives, except where it is not feasible or it is contrary to the best interests of such human beings.

[emphasis  mine]

Note that this section already recognizes situations where informed consent may be waived for practical or ethical reasons.

These rules were in fact promulgated under 45 CFR part 46, section 116. The relevant bit – as far as this conversation goes – regards circumstances under which informed consent might be fully or partially waived. Specifically, there are 4 criteria, all of which need to be met:

 (1) The research involves no more than minimal risk to the subjects;
 (2) The waiver or alteration will not adversely affect the rights and welfare of the subjects;
 (3) The research could not practicably be carried out without the waiver or alteration; and
 (4) Whenever appropriate, the subjects will be provided with additional pertinent information after participation.

In practice, this is an especially difficult set of criteria to meet for most studies. Criterion (1) rules out most “conventional” clinical trials, because the hallmarks of those trials (use of an investigational medicine, randomization of treatment, blinding of treatment allocation) are all deemed to be more than “minimal risk”. That leaves observational studies – but even many of these cannot clear the bar of criterion (3).

That word “practicably” is a doozy.

Here’s an all-too-real example from recent personal experience. A drug manufacturer wants to understand physicians’ rationales for performing a certain procedure. It seems – but there is little hard data – that a lot of physicians do not strictly follow guidelines on when to perform the procedure. So we devise a study: whenever the procedure is performed, we ask the physician to complete a quick form categorizing why they made their decision. We also ask him or her to transcribe a few pieces of data from the patient chart.

Even though the patients aren’t personally identifiable, the collection of medical data qualifies this as a clinical trial.

It’s a minimal risk trial, definitely: the trial doesn’t dictate at all what the doctor should do, it just asks him or her to record what they did and why, and supply a bit of medical context for the decision. All told, we estimated 15 minutes of physician time to complete the form.

The IRB monitoring the trial, however, denied our request for a waiver of informed consent, since it was “practicable” (not easy, but possible) to obtain informed consent from the patient.  Informed consent – even with a slimmed-down form – was going to take a minimum of 30 minutes, so the length of the physician’s involvement tripled. In addition, many physicians opted out of the trial because they felt that the informed consent process added unnecessary anxiety and alarm for their patients, and provided no corresponding benefit.

The end result was not surprising: the budget for the trial more than doubled, and enrollment was far below expectations.

Which leads to two questions:

1.       Did the informed consent appreciably help a single patient in the trial? Very arguably, no. Consenting to being “in” the trial made zero difference in the patients’ care, added time to their stay in the clinic, and possibly added to their anxiety.
2.       Was less knowledge collected as a result? Absolutely, yes. The sponsor could have run two studies for the same cost. Instead, they ultimately reduced the power of the trial in order to cut losses.


Bottom line, it appears that the modifications proposed in the 21st Century Cures Act really only targets trials like the one in the example. The language clearly retains criteria 1 and 2 of the current HHS regs, which are the most important from a patient safety perspective, but cuts down the “practicability” requirement, potentially permitting high quality studies to be run with less time and cost.

Ultimately, it looks like a very small, but positive, change to the current rules.

The rest of the act appears to be a mash-up of some very good and some very bad (or at least not fully thought out) ideas. However, this clause should not be cause for alarm.




act

Hospitals face months of IV fluid shortages after Helene damages N.C. factory

Hospitals have been forced to innovate with new ways of hydrating patients and giving them medications, after a key factory that produces IV fluid bags flooded during Hurricane Helene. (This story first aired on Morning Edition on Nov. 7, 2024.)




act

What does a 2nd Trump term mean for the Affordable Care Act?

President-elect Donald Trump tried unsuccessfully to get rid of the Affordable Care Act during his first term. What action will he take this time around?




act

How Did Attendees at a Behavioral Health Conference React to Trump’s Victory?

When it comes to the effects that the upcoming Trump presidency will have on healthcare, attendees’ attitudes ranged from cautiously optimistic to fairly anxious. Some of the issues they highlighted included mental health parity, telehealth prescribing flexibilities, and the role of Robert F. Kennedy Jr.

The post How Did Attendees at a Behavioral Health Conference React to Trump’s Victory? appeared first on MedCity News.




act

Measuring Impact in Digital Youth Mental Health: What Investors Look For

Many companies are entering the digital youth mental health space, but it’s important to know which ones are effective, according to a panel of investors at the Behavioral Health Tech conference.

The post Measuring Impact in Digital Youth Mental Health: What Investors Look For appeared first on MedCity News.




act

Pew Applauds Michigan for Enacting Bipartisan Legislation to Safely Reduce Jail Populations

The Pew Charitable Trusts today commended Michigan Governor Gretchen Whitmer (D), state Senate Majority Leader Mike Shirkey (R), and Lee Chatfield (R)—whose term as state House Speaker ended last month—for passing and signing a bipartisan package of bills aimed at protecting public safety while reducing the number of people in county jails.




act

Tools to Boost Beneficial Bacteria Can Help Poultry Farms Fight Salmonella

Chicken products cause an estimated 1 in 7 of the nation’s human Salmonella illnesses each year, partly because the pathogen can easily contaminate the environments where birds are raised. To reduce the risk that contaminated meat will reach consumers, poultry companies need measures that control the bacterium on farms where chickens are bred and raised.




act

Standard Technology Presents Opportunities for Medical Record Data Extraction

Technology has revolutionized the way people live their lives. Individuals can use smartphones to access their bank account, shop from almost any store, and connect with friends and family around the globe. In fact, these personal devices have tethered communities together during the coronavirus pandemic, allowing many people to maintain much of their lives remotely.




act

En Banc: Federal Circuit Provides Guidance on Application of On-Sale Bar to Contract Manufacturers

Pharmaceutical and biotech companies breathed a sigh of relief Monday when the Federal Circuit unanimously ruled in a precedential opinion that the mere sale of manufacturing services to create embodiments of a patented product is not a “commercial sale” of the invention that triggers the on-sale bar of 35 U.S.C. § 102(b) (pre-AIA).[1]  The en banc opinion...… Continue Reading




act

Impact of Trump and Harris on Prescription Drug Pricing

The upcoming U.S. presidential election is stirring discussions around healthcare, especially the cost of prescription drugs and the […]

The post Impact of Trump and Harris on Prescription Drug Pricing appeared first on World of DTC Marketing.



  • As I See It
  • Business of the drug industry
  • Cost of healthcare in the U.S.
  • in the news
  • Election & Pharma


act

Impact of Trump on Drug Pricing Policies

With Trump’s victory, healthcare and the pharmaceutical industry could shift significantly. Based on Trump’s first-term policies, his administration […]

The post Impact of Trump on Drug Pricing Policies appeared first on World of DTC Marketing.



  • in the news
  • Changes in healthcare

act

South Korean actor Song Jae-rim dies aged 39, celebrities pay tribute

South Korean actor Song Jae-rim died yesterday (Nov 12) at the age of 39. The Seongdong Police Station in Seoul confirmed that he was found deceased in his apartment at around 12.30pm. According to media reports, a friend whom he was supposed to meet for lunch had visited his home and reported the death. A two-page letter was reportedly found at the scene but the cause of death has not been confirmed. A police official, however, stated that there are "no signs of foul play". His wake was held at Yeouido St. Mary’s Hospital Funeral Hall at 5.30pm yesterday. His funeral will be held tomorrow at Seoul City Crematorium. Jae-rim gained popularity after starring in the 2012 drama The Moon Embracing the Sun and the 2014 reality series We Got Married. This year, he starred in two dramas — My Military Valentine and Queen Woo. Following news of his death, comedian Hong Seok-cheon and other celebrities posted tributes to Jae-rim on social media.




act

Police probing deepfake nude photos of Singapore Sports School students; school meting out disciplinary actions

SINGAPORE – The police are investigating deepfake nude photos of Singapore Sports School (SSP) students that were created and spread by other students. In response to queries from The Straits Times, school principal Ong Kim Soon said SSP is “aware of the incident involving the creation and sharing of deepfake photos by our student-athletes”. “The school does not condone such harmful behaviour,” he said, adding that it has launched an investigation and lodged a police report. The police, in response to queries from ST, confirmed that a report was lodged and investigations are ongoing. A reader who identified himself as a parent of a victim had alerted ST in an e-mail on Nov 12 about the deepfake nude images that were being circulated. “Many parents of affected female students in Singapore Sports School are making police reports about deepfake nude photos of their daughters generated by male students from the school,” the parent said. When contacted, the parent said that female teachers were also targeted, and that the school has offered affected students counselling.




act

Pakistan limits outdoor activities, market hours to curb air pollution-related illness

LAHORE — Pakistan's Punjab province banned most outdoor activities and ordered shops, markets and malls in some areas to close early from Monday (Nov 11) to curb illnesses caused by intense air pollution. The province has closed educational institutions and public spaces like parks and zoos until Nov. 17 in places including Lahore, the world's most polluted city in terms of air quality, according to Swiss group IQAir's live ratings. The districts of Lahore, Multan, Faisalabad and Gujranwala have seen an unprecedented rise in patients with respiratory diseases, eye and throat irritation, and pink eye disease, the Punjab government said in an order issued late on Sunday. The new restrictions will also remain in force until Nov. 17. "The spread of conjunctivitis/ pink eye disease due to bacterial or viral infection, smoke, dust or chemical exposure is posing a serious and imminent threat to public health," the Punjab government said.




act

South Korea's Yoon practices golf to prepare for future Trump meets

SEOUL — South Korean President Yoon Suk-yeol recently began practising golf, for the first time in eight years, in preparation for future meetings with US President-elect Donald Trump, Yoon's office confirmed on Tuesday (Nov 12). South Korean media said Yoon visited a golf course on Saturday for a sport his office said he had last played in 2016. "A lot of people close to President Trump... (told me) President Yoon and Trump will have good chemistry," Yoon told a press conference on Thursday, after congratulating Trump by telephone on his win. Former Trump administration officials and influential Republicans had offered to help build ties with the incoming president, he added. Analysts said Yoon may seek to find a way to capitalise on a personal friendship with Trump to advance Seoul's interests as Trump's "America First" foreign policy plans and his unpredictable style play out in his second term. South Korean companies rely heavily on trade with the United States, and during Trump's first term, the countries clashed over cost-sharing for the roughly 28,500 US troops stationed in South Korea as a legacy of the 1950-1953 Korean War.




act

Noel Kempff Mercado Climate Action Project: The Promise and Peril of High-Potential Environmental Partnerships

In the first comprehensive post-mortem analysis of the Noel Kempff Mercado Climate Action Project (NKMCAP), Reine Rambert and Amanda Sardonis examine how NKMCAP failed to live up to its potential, by focusing on three different dimensions of partnership effectiveness: 1) the sustainability of the partnership, 2) the effectiveness of the collaboration process itself, and 3) the achievement of the planned objectives. Rambert and Sardonis extract several transferable lessons from the challenges faced by NKMCAP that are highly consequential to partnership effectiveness.




act

&lsquo;We have some contacts with bad guys and perhaps one of them did it'

Pakistan's National Security Adviser to the Prime Minister, Mahmud Ali Durrani, on the 2008 bombing of the Indian Embassy in Kabul




act

&lsquo;Pakistan's actions at the UN may embolden other member states to oppose U.S. positions'

U.S. Mission in New York raised concerns about Pakistan's voting on key issues such as counterterrorism and human rights




act

242073: Action request for senior level engagement on terrorism finance

Cutting off the flow of funds to terrorist organizations and achieving stability in Af/Pak are top U.S. priorities.




act

6 Months On: What is the Impact of the War in Gaza?

6 months on: What is the impact of the war in Gaza?
Brookings experts reflect on the conflict




act

The impact of Iran’s attack on Israel

Brookings scholars offer their insights following Iran’s drone and missile attack against Israel on April 13, 2024. Their responses provide perspectives on the implications for various actors as well as a range of policy issues.








act

We All Fall Down: The Dismantling of the Warsaw Pact and the End of the Cold War in Eastern Europe

The non-Soviet members of the Warsaw Pact contributed to the end of the Cold War along with the superpowers. These Eastern European states recognized that their relationship with the Soviet Union would impede their success in the post–Cold War world, so they ended the Pact.




act

Nobody Actually Knows What Russia Does Next

Stephen Walt argues that because no one knows what Putin might do, NATO's European members should increase their defense capabilities and correct any obvious vulnerabilities. At the same time, however, the United States and its NATO allies should acknowledge Russia's legitimate security concerns and consider what they can do to allay them.




act

Event Debrief: Why the Inflation Reduction Act Passed

Harvard Kennedy School hosted Leah Stokes, Anton Conk Associate Professor of Environmental Politics at UC Santa Barbara, to discuss how the historic Inflation Reduction Act succeeded where so many previous climate bills failed.




act

Democratic Transitions and Conflict Zones: The Impact on Policy-Making in Africa

On March 26, the study group met for the first time to examine recent democratic progress and backsliding in African countries. The session focused on ongoing conflicts in different regions of Africa and examined their political underpinnings. Participants also discussed the role of third-party actors in supporting and facilitating conflict mediation and peacebuilding efforts in the continent. The study group counted with the presence of external expert guest Dr. Antje Herrberg, Chief of Staff of the European Union Capacity Building Mission in Niger (EUCAP Sahel Niger). Dr. Herrberg brings more than two decades of professional and personal experience in transition and conflict resolution, intractable conflict, and terrorism with a deep interest to alleviate the suffering of people. Furthermore, Florian Dirmayer, Master in Public Policy Candidate at Harvard Kennedy School, delivered a memo briefing on European Union Security Cooperation with Niger After the 2023 Military Coup.




act

Strategic Myopia: The Proposed First Use of Tactical Nuclear Weapons to Defend Taiwan

David Kearn argues that the idea that the first use of nuclear weapons since 1945 would be by the United States in the defense of Taiwan against a conventional Chinese invasion would have significant, negative, and long-lasting, diplomatic ramifications. It is difficult to fathom the myriad potential consequences, but U.S. nuclear weapon use would almost certainly shatter the non-proliferation regime as a functioning entity, incentivize states (including China) to acquire or improve their existing nuclear arsenal, and damage America's standing globally.




act

Russia's Invasion of Ukraine and Its Impact on the Global Nuclear Order

Mariana Budjeryn presents "Russia's Invasion of Ukraine and Its Impact on the Global Nuclear Order" at the DOE/NNSA Administrator's Strategy Forum




act

When Actions Speak Louder Than Words: Adversary Perceptions of Nuclear No-First-Use Pledges

Would the world be safer if the United States pledged to never use nuclear weapons first? Supporters say a credible pledge would strengthen crisis stability, decrease hostility, and bolster nonproliferation and arms control. But reactions to no-first-use pledges by the Soviet Union, China, and India suggest that adversaries perceive pledges as credible only when the political relationship between a state and its adversary is already relatively benign, or when the state’s military has no ability to engage in nuclear first use against the adversary. 




act

Impacts of Electric Vehicle Subsidies: A Conversation with Hunt Allcott

Behavioral economist Hunt Allcott, Professor of Global Environmental Policy at the Doerr School of Sustainability at Stanford University, questioned the impact of new and used electric vehicle (EV) subsidies in the latest episode of “Environmental Insights: Discussions on Policy and Practice from the Harvard Environmental Economics Program.”




act

Leveraging Charging Strategies to Reduce Grid Impacts of Electric Vehicles

Electric vehicles (EVs) can challenge or support electricity systems depending on how they are charged. Controlled charging that combines technical solutions with heterogenous EV user behaviors can reduce peak demand to avoid grid constraints and support the integration of renewable energy.




act

Harvard Project Director Robert Stavins Moderates Climate Action Week Panel on “Strategies for Mitigating Global Methane Emissions”

Efforts to measure and mitigate the impact of methane emissions was the topic of discussion last Monday (June 10, 2024) at a panel convened as part of Climate Action Week in the Northwest Building, sponsored by Harvard’s Salata Institute for Climate and Sustainability and moderated by Harvard Environmental Economics Program and Harvard Project Director Robert Stavins.




act

Former Residents of Huronia, Rideau, and Southwestern Regional Centres Could Receive Compensation from Class Action Settlements - Settlement Overview Video

Settlement Overview Video. If you lived at Huronia, Rideau, or Southwestern Regional Centres, you may be eligible to make a claim.




act

Survey Finds Gap Between Home Protection Concerns And Consumer Actions - Kristin Chenoweth Protect It Or Lose It Video

Kristin Chenoweth teamed up with Allstate to quiz homeowners on the value of the possessions in their home - see what they know, and don't know!